ZLCS Share Price

Open 1.15 Change Price %
High 1.29 1 Day 0.03 2.61
Low 1.12 1 Week 0.00 0.00
Close 1.18 1 Month 0.00 0.00
Volume 1155992 1 Year 0.00 0.00
52 Week High 6.67
52 Week Low 3.78
ZLCS Important Levels
Resistance 2 1.34
Resistance 1 1.27
Pivot 1.20
Support 1 1.09
Support 2 1.02
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
ATEA 2.50 32.98%
ATEA 2.50 32.98%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
BGMD 0.05 25.00%
ATRM 1.70 21.43%
MIND 3.33 15.62%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
DCIX 0.26 -40.91%
More..

Zalicus Inc. (NASDAQ: ZLCS)

ZLCS Technical Analysis 2
As on 15th Jul 2014 ZLCS Share Price closed @ 1.18 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.57 & Buy for SHORT-TERM with Stoploss of 1.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
ZLCS Target for August
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ZLCS Other Details
Segment EQ
Market Capital 70786440.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.zalicus.com
ZLCS Address
ZLCS
245 First Street
Third Floor
Cambridge, MA 02142
United States
Phone: 617-301-7000
Fax: 617-301-7010
ZLCS Latest News
Why Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) Shares Are Up Nearly 7%   Small Cap Exclusive (press release)   - 19th Jul 16
Boston drug firm's shares slump due to job cuts, cash shortage   Boston Business Journal (blog)   - 10th May 16
EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars ...   GlobeNewswire (press release)   - 10th May 16
EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 ...   GlobeNewswire (press release)   - 15th Mar 16
EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for ...   GlobeNewswire (press release)   - 09th Feb 16
EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through ...   GlobeNewswire (press release)   - 09th Sep 15
EPIRUS Biopharmaceuticals and Polpharma Group Enter Into a Multi-Product ...   GlobeNewswire (press release)   - 14th Jul 15
Epirus Biopharma: A High Risk/High Reward Biosimilar Investment   Seeking Alpha   - 31st Dec 14
EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS ...   Business Wire (press release)   - 15th Jul 14
Zalicus' Z160 Fails, What Now?   Seeking Alpha   - 11th Nov 13
Interactive Technical Analysis Chart Zalicus Inc. ( ZLCS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Zalicus Inc.
ZLCS Business Profile
Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. It focuses on the discovery and development of selective ion channel modulators and its combination high throughput screening technology (cHTSTM) to discover new product candidates for its portfolio or for its collaborators in the areas of pain, inflammation, oncology and infectious disease.